B.C. Cho

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib

H. Horinouchi, B.C. Cho, D.R. Camidge et al. · Annals of Oncology · 2025 · 33 citations · Full text

Medicine, Oncology, Pharmacology +12

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

N. B. Leighl, Catherine A. Shu, Anna Minchom et al. · Annals of Oncology · 2021 · 32 citations

Medicine, Oncology, Pharmacology +8

10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial

N. Girard, Wei Li, A.I. Spira et al. · Journal of Thoracic Oncology · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +10

OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%

T.J.N. Hiltermann, Hiroki Izumi, B.C. Cho et al. · Journal of Thoracic Oncology · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17